Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Sino Biopharmaceutical ( (HK:1177) ).
Sino Biopharmaceutical has received approval from the Center for Drug Evaluation of China to initiate a Phase III clinical study for its innovative drug, TQB2868 injection, aimed at treating metastatic pancreatic ductal adenocarcinoma (mPDAC). This drug, combined with anlotinib hydrochloride capsules and chemotherapy, has shown promising results in early trials, potentially becoming a groundbreaking first-line treatment option for pancreatic cancer, which currently has limited effective treatments and a low survival rate.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a company in the pharmaceutical industry, focusing on the development of innovative drugs. The company is involved in creating advanced treatments, particularly in the field of oncology, with a market focus on addressing unmet medical needs.
Average Trading Volume: 112,225,674
Technical Sentiment Signal: Buy
Current Market Cap: HK$81.38B
For a thorough assessment of 1177 stock, go to TipRanks’ Stock Analysis page.